Think More & Change

The Multiple Angiogenic Factor Trap\(^1\) - ZALTRAP\(^*\)

ZALTRAP\(^*\), the only 2nd line treatment option in patients with mCRC that shows significant improvements in OS, PFS and ORR, in combination with FOLIRI\(^*\)!^4

More blockage of angiogenic factors\(^1\)
More treatment options\(^1\)
More heterogeneous population\(^2\)

*ZALTRAP* contains standardali dose levels within a month of starting metastatic colorectal therapy

Program Book

---

44th Annual Meeting & 4th International Cancer Conference

Korean Cancer Association

June 21(Thu)-22(Fri), 2018
Lotte Hotel Seoul, Korea
Welcome Message

Scientific Committee

Program at a Glance

Venue Layout

Exhibition

Meeting Information

Daily Program

Poster Presentations
Welcome Message

Dear Colleagues and Friends,

Welcome to the 44th Annual Meeting of Korean Cancer Association and the 4th International Cancer Conference, which will be held from June 21 to 22, 2018, in Seoul, Korea.

As one of the most authoritative scientific society in the field of oncology, KCA has held annual meetings with its the best program to foster knowledge and encourage collaboration among international participants.

This year’s meeting will be a blend of invited lectures and selected presentations, which will offer an opportunity for valuable discussion and note swapping on cancer treatment. Over 360 abstracts from 19 countries will be presented to cover a broad spectrum of research in cancer and related biomedical science around Asia.

We would like to convey our sincere gratitude to all the speakers, chairs, and sponsors for their contribution for the meeting. Also, we thank our scientific committee members for their heartfelt efforts in making this year’s program.

Thank you for your participation and we wish you all a stimulating meeting as well as a great time in Seoul.

Sincerely yours,

Eun Kyung Choi, M.D., Ph.D.
President
Korean Cancer Association

Yeul Hong Kim, M.D., Ph.D.
Chairman, Board of Directors
Korean Cancer Association

Tae You Kim, M.D., Ph.D.
Chair, Scientific Committee
Korean Cancer Association

Scientific Committee

Chairperson
Tae You Kim
Seoul National University College of Medicine

Vice-chairperson
Dae-Ho Lee
University of Ulsan College of Medicine

Members
Eui Kyu Chie
Seoul National University College of Medicine

Gi Jeong Cheon
Seoul National University College of Medicine

Jae Yong Cho
Yonsei University College of Medicine

Yeun-Jun Chung
The Catholic University of Korea College of Medicine

Sang-Jun Ha
Yonsei University College of Life Science and Biotechnology

Byoung-Gie Kim
Sungkyunkwan University School of Medicine

Jae Weon Kim
Seoul National University College of Medicine

Jin Kim
Korea University College of Medicine

Tae Min Kim
Seoul National University College of Medicine

Young Woo Kim
National Cancer Center

Hyunsook Lee
Seoul National University

Jeeyun Lee
Sungkyunkwan University School of Medicine

Sug Hyung Lee
The Catholic University of Korea College of Medicine

Yeon-Su Lee
National Cancer Center

Kyong-Hwa Park
Korea University College of Medicine

In Ja Park
University of Ulsan College of Medicine
# Thursday, June 21

<table>
<thead>
<tr>
<th>Location</th>
<th>Crystal Ballroom (2F)</th>
<th>Pine Room (3F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td>Room A</td>
<td>Room B</td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:40</td>
<td>ES-1 [ENG] Foundation of precision oncology</td>
<td>ES-2 [ENG] Progress in surgical treatment for malignant disease</td>
</tr>
<tr>
<td></td>
<td>SP-1 [ENG] Emerging molecular segments in gastrointestinal cancer</td>
<td></td>
</tr>
<tr>
<td>10:40 - 11:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>PL-1 [ENG] Prof. Ho-Young Lee</td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:20</td>
<td>PL-2 [ENG] Dr. Peter Campbell</td>
<td></td>
</tr>
<tr>
<td>12:20 - 13:20</td>
<td>SS-1 [ENG] (by MSD)</td>
<td></td>
</tr>
<tr>
<td>13:20 - 15:00</td>
<td>SP-3 [ENG] Plasma genotyping for precision medicine</td>
<td>SP-4 [ENG] Change of surgical strategy by multidisciplinary treatment</td>
</tr>
<tr>
<td></td>
<td>SP-5 [ENG] Key issues in biosimilars</td>
<td>SP-6 [ENG] Multifocal lung cancer; The same or different? Aggressive or conservative?</td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:20 - 17:00</td>
<td>SP-9 [ENG] Personalized cancer immunotherapy</td>
<td>SP-10 [ENG] Hospice and palliative care</td>
</tr>
<tr>
<td></td>
<td>SP-11 [ENG] Genomic alterations in premalignant lesions</td>
<td></td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>IS-1 [ENG] Basic research 1</td>
<td>IS-2 [ENG] Basic research 2</td>
</tr>
<tr>
<td></td>
<td>IS-3 [ENG] Lung and H&amp;N cancer (HBP, Colorectal)</td>
<td>IS-4 [ENG]</td>
</tr>
<tr>
<td></td>
<td>IS-5 [ENG] Radiotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IS-6 [ENG] Supportive care, pediatric cancer and radiation oncology</td>
<td></td>
</tr>
</tbody>
</table>

**Session Remarks**

SP-03 Joint Symposium (Korean Cancer Association & Korean Society for Laboratory Medicine)
SP-08, 14 Joint Symposia (Korean Cancer Association & Shanghai Cancer Institute)
SP-11 Joint Symposium (Korean Cancer Association & The Korean Society of Pathologists)
SP-12 The Center for Korean Users of Heavy-Ion Facilities Symposium

---

**Thursday, June 21**

<table>
<thead>
<tr>
<th>Location</th>
<th>Sapphire Ballroom (3F)</th>
<th>Belle-ville Suite (36F)</th>
<th>Emerald (2F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room A</td>
<td>SP-2 [ENG] Clinical trials and molecular imaging biomarkers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room B</td>
<td>YIS [KOR] Young Investigator Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:40</td>
<td>ES-3 [ENG] Genomic and immuno-oncology era in radiation oncology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:40 - 11:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>SP-7 [ENG] Recent progress in cancer epigenomics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:20</td>
<td>SP-8 [ENG] Microenvironment and tumorigenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20 - 13:20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:20 - 15:00</td>
<td>ES-3 [ENG] by (ONO/BMS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:20</td>
<td>SP-7 [ENG]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:20 - 17:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 18:00</td>
<td>IS-5 [ENG] Radiation oncology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IS-6 [ENG]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Conference Information**

PL: Plenary Lecture  MC: Master Class  OP: Oral Presentation
ES: Educational Session  SS: Satellite Symposium  EN: Session in English
SP: Symposium  IS: International Session  KOR: Session in Korean
## Session Remarks

**SP-15** National OncoVenture Symposium  
**SP-19** Joint Symposium (Korean Cancer Association & Korea Genome Organization)  
**SP-21** Joint Symposium (Korean Cancer Association & Korean Society of Gynecologic Oncology)  
**SP-23** Joint Symposium (Korean Cancer Association & Beijing Medical Association)

### Friday, June 22

<table>
<thead>
<tr>
<th>Location</th>
<th>Crystal Ballroom (2F)</th>
<th>Pine Room (3F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room A</td>
<td>Room B</td>
<td>Room C</td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td></td>
<td>Registration</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td><strong>Outstanding Abstract Session</strong></td>
<td>Basic research 3</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:20 - 10:50</td>
<td><strong>PL-3</strong> Prof. Dong-Young Noh</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:40</td>
<td><strong>PL-4</strong> Prof. Frank McCormick</td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:50</td>
<td><strong>SS-4</strong> (by Roche)</td>
<td></td>
</tr>
<tr>
<td>12:50 - 13:20</td>
<td>KCA General Assembly</td>
<td></td>
</tr>
<tr>
<td>13:20 - 13:40</td>
<td></td>
<td>Break</td>
</tr>
<tr>
<td>13:40 - 15:20</td>
<td><strong>SP-15</strong> From scientific lead to companion diagnostics (CDx) approval process in Korea</td>
<td><strong>IS-8</strong> Gynecologic Cancer</td>
</tr>
<tr>
<td>15:20 - 15:40</td>
<td></td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:40 - 17:20</td>
<td><strong>SP-20</strong> Multidisciplinary care of BRCA mutation carriers</td>
<td><strong>SP-16</strong> Gynecologic cancer</td>
</tr>
<tr>
<td>17:30 - 19:00</td>
<td>Closing Reception @ Belle-vue Suite (36F)</td>
<td></td>
</tr>
</tbody>
</table>

**Session in English**  
**Session in Korean**

---

### Friday, June 22

<table>
<thead>
<tr>
<th>Location</th>
<th>Sapphire Ballroom (3F)</th>
<th>Belle-vue Suite (36F)</th>
<th>Emerald (2F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room A</td>
<td>Room B</td>
<td>Room C</td>
<td></td>
</tr>
<tr>
<td>08:00 - 09:00</td>
<td></td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td><strong>OP-3</strong> H&amp;N and other cancers</td>
<td><strong>OP-4</strong> Colorectal cancer</td>
<td><strong>IS-7</strong> Lung cancer</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td></td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:50</td>
<td><strong>SS-5</strong> (by Lilly)</td>
<td><strong>SS-6</strong> (by Pfizer)</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:50</td>
<td><strong>SP-17</strong> Head and neck cancer</td>
<td><strong>SP-18</strong> Current debate in the oncologic management of rectal cancer</td>
<td><strong>MC-4</strong> A forum on tumor microenvironment</td>
</tr>
<tr>
<td>12:50 - 13:20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:20 - 13:40</td>
<td></td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>13:40 - 15:20</td>
<td><strong>IS-11</strong> Genitourinary cancer</td>
<td><strong>SP-23</strong> Tumor immunity and immunotherapy</td>
<td><strong>IS-12</strong> Genitourinary cancer</td>
</tr>
<tr>
<td>15:20 - 15:40</td>
<td></td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>15:40 - 17:20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 19:00</td>
<td>Closing Reception @ Belle-vue Suite (36F)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PL** : Plenary Lecture  
**MC** : Master Class  
**OP** : Oral Presentation  
**SL** : Special Lecture  
**SS** : Satellite Symposium  
**SP** : Symposium  
**IS** : International Session  
**ENG** : Session in English  
**KOR** : Session in Korean

---

**Poster Presentation 2** (09:00 - 17:00)

---

**Closing Reception @ Belle-vue Suite (36F)**
Meeting Information

SPEAKER’S PREVIEW ROOM
Speakers are requested to visit the preview room (Jade Room, 2F) and submit presentation materials at least 1 hour prior to their scheduled session.

- June 21 (Thu) 08:00 - 18:00
- June 22 (Fri) 08:00 - 17:00

POSTER PRESENTATION
Posters will be displayed from 09:00-17:00 in the Emerald Room (2F).

<table>
<thead>
<tr>
<th>Poster Session 1</th>
<th>Date</th>
<th>Set up</th>
<th>Display</th>
<th>Removal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Session 1</td>
<td>June 21 (Thu)</td>
<td>08:00-09:00</td>
<td>09:00-17:00</td>
<td>17:00-18:00</td>
</tr>
<tr>
<td>Poster Session 2</td>
<td>June 22 (Fri)</td>
<td>08:00-09:00</td>
<td>09:00-17:00</td>
<td>17:00-18:00</td>
</tr>
</tbody>
</table>

INTERNET LOUNGE WITH CAFE
Internet lounges will be located in the Emerald Room Lobby (2F) and Sapphire Ballroom Lobby (3F) on the following schedule.

- June 21 (Thu) 09:00 - 18:00
- June 22 (Fri) 09:00 - 17:00

SATELLITE SYMPOSIA (LUNCH PROVIDED)
Luncheon will be provided during satellite symposia. Please display your name badge to receive your lunchbox.

<table>
<thead>
<tr>
<th>Place / Time</th>
<th>June 21 (Thu) 12:20-13:20</th>
<th>June 22 (Fri) 11:50-12:50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystal Ballroom (2F)</td>
<td>MSD, Roche</td>
<td>Boehringer Ingelheim Korea, Bayer Korea, Shire Pharma Korea</td>
</tr>
<tr>
<td>Sapphire Ballroom B (3F)</td>
<td>ONO PHARMA KOREA, Bristol-Myers Squibb</td>
<td>Novartis, Roche</td>
</tr>
<tr>
<td>Sapphire Ballroom C (3F)</td>
<td>Novartis, Roche</td>
<td>Novartis, Roche</td>
</tr>
</tbody>
</table>

CLOSING RECEPTION
Closing reception with the Merit Awards ceremony will be held on June 22, 17:30 in the Belle-vue Suite (36F).
### Educational Session 1

**Foundation of precision oncology**

**Chairs**
- Sun Young Rha (Yonsei University College of Medicine)
- Hyunsook Lee (Seoul National University)

**ES1-1**
- Deep learning for predicting cancer vulnerabilities in clinical samples
  - Jung Kyoon Choi (Korea Advanced Institute of Science and Technology (KAIST))

**ES1-2**
- Application of PDX technology combined with cancer genome information for precision oncology
  - Jong-Il Kim (Seoul National University College of Medicine)

**ES1-3**
- Multi-platform genomic and epigenomic landscape of liver cancer development and progression
  - Hyun Goo Woo (Ajou University School of Medicine)

**ES1-4**
- Precision oncology platform for oncologists
  - Jeeyun Lee (Sungkyunkwan University School of Medicine)

### Educational Session 2

**Progress in surgical treatment for malignant disease**

**Chairs**
- Kyung Sik Kim (Yonsei University College of Medicine)
- Moo-Jun Baek (Soonchunhyang University Cheonan Hospital)

**ES2-1**
- Pylorus preserving gastrectomy and KLASS-04
  - Hyuk-Joon Lee (Seoul National University College of Medicine)

**ES2-2**
- Laparoscopic liver resection: Real advantage?
  - Ki-Hun Kim (University of Ulsan College of Medicine)

**ES2-3**
- Breast reconstruction: related to the better life?
  - Jeong Eon Lee (Sungkyunkwan University School of Medicine)

**ES2-4**
- Robotic rectal cancer surgery surpasses laparoscopic resection
  - Gyu-Seog Choi (Kyungpook National University School of Medicine)
### Symposium 1  **Emerging molecular segments in gastrointestinal cancer**

**Chairs**
Sug Hyung Lee (The Catholic University of Korea College of Medicine)
Jae Yong Cho (Yonsei University College of Medicine)

**SP01-1**
**Overcoming tumor heterogeneity in GI cancer: the PANGEA trial**
Daniel Catenacci (University of Chicago, USA)

**SP01-2**
**Emerging molecular target therapy in gastrointestinal cancers**
Keun-Wook Lee (Seoul National University Bundang Hospital)

**SP01-3**
**A close look into the immune signature of gastric cancer**
Taroh Satoh (Osaka University Graduate School of Medicine, Japan)

---

### Symposium 2  **Clinical trials and molecular imaging biomarkers**

**Chairs**
Yong Chan Ahn (Sungkyunkwan University School of Medicine)
Keon Wook Kang (Seoul National University College of Medicine)

**SP02-1**
**Quantitative imaging of cancer to precisely phenotype patients and tumors, to predict and assess treatment response**
Richard Leo Wahl (Washington University School of Medicine in St. Louis, USA)

**SP02-2**
**Role of imaging in lymphoma**
Joo Hyun O (The Catholic University of Korea College of Medicine)

**SP02-3**
**Molecular imaging biomarkers in lung and esophageal cancers for clinical trials**
Joon Young Choi (Sungkyunkwan University School of Medicine)

**SP02-4**
**Role of metabolic imaging in response assessment to standardized chemotherapy in advanced gastric cancer**
Seunggyun Ha (Seoul National University College of Medicine)

---

### Young Investigator Symposium  **Spliceosomal gene mutations in cancer**

**Chairs**
Woochul Noh (Korea Institute of Radiological & Medical Sciences)
Suhwan Chang (University of Ulsan College of Medicine)

**YIS-1**
**Spliceosomal gene mutations in cancer**
Eunhee Kim (Ulsan National Institute of Science and Technology (UNIST))

**YIS-2**
**Genomic alterations of circulating tumor DNA in breast cancer patients**
Jisun Kim (University of Ulsan College of Medicine)

**YIS-3**
**Architecture of genomic rearrangements molding fusion oncogenes in lung adenocarcinomas**
Young Seok Ju (Korea Advanced Institute of Science and Technology (KAIST))

**YIS-4**
**Genome-wide association study for thyroid cancer and thyroid diseases**
Yul Hwangbo (National Cancer Center)

---

### Master Class 1  **Time-traveling in the IO space:**

**Investigate the current status and foresight the IO space**

**Chairs**
Sang We Kim (University of Ulsan College of Medicine)
Michael Holmes (MSD, USA)

**MC1-1**
**Past: What happened? Overview of Keynote trials**
Byoung Chul Cho (Yonsei University College of Medicine)

**MC1-2**
**Present: What's going on? Moving from indistinct approaches to a patient specific approach using biomarker**
Andrey Loboda (MSD, USA)

**MC1-3**
**Future: What's coming? Define future clinical combination strategy?**
Michael Holmes (MSD, USA)
Plenary Lecture 1  
**ENG**  
11:00-11:30, Crystal Ballroom (2F)  
Chair: Eun Kyung Choi (University of Ulsan College of Medicine)  
PL1:  
**Key strategies to overcome anticancer drug resistance in non-small cell lung cancer**  
Ho-Young Lee (Seoul National University College of Pharmacy)  

Plenary Lecture 2  
**ENG**  
11:30-12:20, Crystal Ballroom (2F)  
Chair: Yeul Hong Kim (Korea University College of Medicine)  
PL2:  
**Interrogating the architecture of cancer genomes**  
Peter Campbell (Wellcome Trust Sanger Institute, UK)  

Satellite Symposium 1  
**ENG**  
* by MSD  
12:20-13:20, Crystal Ballroom (2F)  
Chair: Ki Hyeong Lee (Chungbuk National University College of Medicine)  
SS1:  
**The art of immunotherapy in NSCLC**  
Ji-Youn Han (National Cancer Center)  

Satellite Symposium 2  
**ENG**  
* by ONO/BMS  
12:20-13:20, Sapphire Ballroom B (3F)  
Chair: Hyun Cheol Chung (Yonsei University College of Medicine)  
SS2:  
**Emerging horizons in gastric cancer immunotherapy**  
Min-Hee Ryu (University of Ulsan College of Medicine)  

Satellite Symposium 3  
**ENG**  
* by Novartis  
12:20-13:20, Sapphire Ballroom C (3F)  
Chair: Jin Hyoung Kang (The Catholic University of Korea College of Medicine)  
SS3:  
**Ceritinib: How to optimize treatment of ALK + NSCLC in 1L**  
Byoung Chul Cho (Yonsei University College of Medicine)  

Symposium 3  
**ENG**  
13:20-15:00, Crystal Ballroom A (2F)  
* Joint Symposium (KCA & Korean Society for Laboratory Medicine)  
**Plasma genotyping for precision medicine**  
Chairs: Sang We Kim (University of Ulsan College of Medicine)  
Chang Ho Jeon (Catholic University of Daegu)  
SP03-1:  
**Circulating tumor DNA as a liquid biopsy: Overview**  
Jong-Won Kim (Sungkyunkwan University School of Medicine)  
SP03-2:  
**cfDNA EGFR mutation detection**  
Kyung A Lee (Yonsei University College of Medicine)  
SP03-3:  
**Plasma genotyping for breast and other cancers**  
Sun-Young Kong (National Cancer Center)  
SP03-4:  
**Plasma sequencing for chromosomal instability detection**  
Eunhae Cho (Green Cross Genome)  

Symposium 4  
**ENG**  
13:20-15:00, Crystal Ballroom B (2F)  
**Change of surgical strategy by multidisciplinary treatment**  
Chairs: Keun Won Ryu (National Cancer Center)  
Myung Ah Lee (The Catholic University of Korea College of Medicine)  
SP04-1:  
**Upfront surgery vs. neoadjuvant chemotherapy for marginally resectable pancreatic cancer**  
Kyu-pyo Kim (University of Ulsan College of Medicine)  
SP04-2:  
**Reality of rectum preservation for locally advanced rectal cancer after preoperative chemoradiotherapy**  
Kil Yeon Lee (Kyung Hee University School of Medicine)  
SP04-3:  
**Conversion surgery after systemic chemotherapy for metastatic gastric carcinoma**  
Oh Jeong (Chonnam National University Medical School)  
SP04-4:  
**Determination of lymph node dissection after neoadjuvant chemotherapy for breast cancer**  
Eun Sook Lee (National Cancer Center)
Symposium 5  
**KOR**

13:20-15:00, Crystal Ballroom C (2F)

**Key issues in biosimilars**

**Chairs**  
Ki Hyeong Lee (Chungbuk National University College of Medicine)  
Kyung Hae Jung (University of Ulsan College of Medicine)

**SP05-1**  
Approaches and interactions in biosimilar development  
HoUng Kim (Celltrion Healthcare)

**SP05-2**  
Regulatory reviewer’s perspective of MFDS  
Jong Won Kim (NIFDS/MFDS)

**SP05-3**  
Biosimilars: Ready to trust them? : from a clinician’s perspective  
In Hae Park (National Cancer Center)

**SP05-4**  
To be an interchangeable drug: Future direction of research  
Tae-Yong Kim (Seoul National University Hospital)

Symposium 6  
**ENG**

13:20-15:00, Pine Room (3F)

**Multifocal lung cancer: The same or different? Aggressive or conservative?**

**Chairs**  
Dae-Ho Lee (University of Ulsan College of Medicine)  
Sehoon Choi (University of Ulsan College of Medicine)

**SP06-1**  
Multifocal lung cancers: second primary or intrapulmonary metastasis?  
Hyae Young Kim (National Cancer Center)

**SP06-2**  
Multifocal lung cancer: The same or different? Aggressive or conservative? - Pathologist’s view  
Hyojin Kim (Seoul National University Bundang Hospital)

**SP06-3**  
Multifocal lung cancers: Thoracic surgeon’s view  
Sehoon Choi (University of Ulsan College of Medicine)

**SP06-4**  
Medical oncologist’s view  
Min Hee Hong (Yonsei University College of Medicine)

Educational Session 3  
**KOR**

13:20-15:00, Sapphire Ballroom A (3F)

**Genomic and immuno-oncology era in radiation oncology**

**Chairs**  
Joo Young Kim (National Cancer Center)  
Ikjae Lee (Yonsei University College of Medicine)

**ES3-1**  
Maneuvering or mining the “BIGGER” data  
O Kyu Noh (Ajou University School of Medicine)

**ES3-2**  
Genomic and immunogenomic approach for prediction of radiation response  
In Ah Kim (Seoul National University College of Medicine)

**ES3-3**  
Immune-modulating radiotherapy or vice versa  
Si Yeol Song (University of Ulsan College of Medicine)

**ES3-4**  
Precision medicine based on RadioGenome using artificial intelligence  
Wonil Jang (Korea Institute of Radiological & Medical Sciences)

Symposium 7  
**ENG**

13:20-15:00, Sapphire Ballroom B (3F)

**Recent progress in cancer epigenomics**

**Chairs**  
Sung-Soo Yoon (Seoul National University College of Medicine)  
Yeon-Su Lee (National Cancer Center)

**SP07-1**  
Targeted bisulfite sequencing of DNA methylation markers for blood-based detection of colorectal cancers  
Gyeong Hoon Kang (Seoul National University College of Medicine)

**SP07-2**  
Functional unit of regulatory elements in breast cancer  
Kyung Hyun Ryu (Sookmyung Women’s University)

**SP07-3**  
Function of TET methylcytosine oxidases in cancer  
Myunggon Ko (Ulsan National Institute of Science and Technology (UNIST))

**SP07-4**  
Nuclear export of HP1γ is responsible for p53 degradation in cervical cancer  
So Hee Kwon (Yonsei University College of Pharmacy)
Symposium 8  
Microenvironment and tumorigenesis 1

**Joint Symposium (KCA & Shanghai Cancer Institute)**

**Chairs**
- Zhi-Gang Zhang (Shanghai Cancer Institute, China)
- Su-Jae Lee (Hanyang University)

**SP08-1**
- Enriched environment boosts NK cell anti-tumor immunity via peripheral sympathetic nerves  
  Yu Gan (Shanghai Cancer Institute, China)

**SP08-2**
- Elimination of a specific subpopulation of T cells overcomes castration-resistance in prostate cancer therapy  
  Wei-Qiang Gao (Shanghai Cancer Institute, China)

**SP08-3**
- The mechanism and pathological features of the oncogenic KRAS stabilization by APC loss in colorectal cancer  
  Kang-Yell Choi (Yonsei University College of Life Science and Biotechnology)

**SP08-4**
- Metabolic regulation of hypoxia responses  
  Young Il Yeom (Korea Research Institute of Bioscience & Biotechnology (KRIBB))

Symposium 9  
Personalized cancer immunotherapy

**Chairs**
- Se-Ho Park (Korea University)
- Sang-Jun Ha (Yonsei University)

**SP09-1**
- Generation of memory type antigen-specific cytotoxic T cells using MHC/peptide complex  
  Se-Ho Park (Korea University)

**SP09-2**
- Microbiome and precision medicine  
  Hansoo Park (Gwangju Institute of Science and Technology (GIST))

**SP09-3**
- Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma  
  Shinichi Makita (National Cancer Center Hospital, Japan)

**SP09-4**
- Computational prediction of somatic mutation driven neoantigens  
  Sangwoo Kim (Yonsei University College of Medicine)

Symposium 10  
Hospice and palliative care

**Chairs**
- Kyung Hee Lee (Yeungnam University College of Medicine)
- Dae-Ho Lee (University of Ulsan College of Medicine)

**SP10-1**
- Hospice and palliative care policy in South Korea  
  Yoon-Jung Chang (National Cancer Center)

**SP10-2**
- Hospice and palliative care services in Korea: focused on terminal cancer patients  
  Jung Hye Kwon (Kangdong Sacred Heart Hospital)

**SP10-3**
- Practice case of hospice and palliative care for terminal cancer patients (inpatient, home care, shared care)  
  Su-Jin Koh (Ulsan University Hospital)

Q&A
**Symposium 11**  
**Genomic alterations in premalignant lesions**

*Joint Symposium (KCA & The Korean Society of Pathologists)*

<table>
<thead>
<tr>
<th>Chairs</th>
</tr>
</thead>
</table>
| Woo Ho Kim (Seoul National University College of Medicine)  
| Kyoung-Mee Kim (Sungkyunkwan University School of Medicine) |  

**SP11-1** Genomic alterations in gastric cancer precursor lesions  
Kyoung-Mee Kim (Sungkyunkwan University School of Medicine)

**SP11-2** Genomic alterations in dysplastic nodule and early hepatocellular carcinoma  
Young Nyun Park (Yonsei University College of Medicine)

**SP11-3** Genomic alterations in preinvasive lesions of lung cancer  
Hyo Sup Shim (Yonsei University College of Medicine)

**SP11-4** Molecular alterations in serrated precursor lesions of colorectal cancer  
Jung Ho Kim (Seoul National University Hospital)

---

**Symposium 12**  
**Bio-medical research using big accelerators**

*The Center for Korean Users of Heavy-Ion Facilities Symposium*

<table>
<thead>
<tr>
<th>Chairs</th>
</tr>
</thead>
</table>
| Woo-Yoon Park (Chungbuk National University College of Medicine)  
| Kyung Hwan Shin (Seoul National University College of Medicine) |  

**SP12-1** Potential use of synchrotron radiation for bio-medical studies  
Jae-Hong Lim (Pohang Accelerator Laboratory)

**SP12-2** The status of KOMAC and its bio-medical applications  
Kye Ryung Kim (Korea Atomic Energy Research Institute (KAERI))

**SP12-3** Status and opportunities for medical research with RAON  
Young Kwan Kwon (Institute for Basic Science (IBS))

**SP12-4** Biomedical research using heavy ions  
Sei Sai (National Institutes for Quantum and Radiological Science and Technology, Japan)

---

**Symposium 13**  
**Optimization of adjuvant systemic treatment for EBC**

| Chairs | Young Hyuck Im (Sungkyunkwan University School of Medicine)  
| In Sook Woo (The Catholic University of Korea College of Medicine) |  

**SP13-1** Personalized approach in breast cancer to balance treatment outcome and patients quality of life  
Edith A. Perez (Mayo Clinic, USA)

**SP13-2** Optimal duration and treatment for ER(+) breast cancer: Current evidence and future  
Jee Hyun Kim (Seoul National University Bundang Hospital)

**SP13-3** Ramification of adjuvant anti-HER2 treatment: The more is the better?  
Keeun Seok Lee (National Cancer Center)

**SP13-4** Better strategies of adjuvant treatment for TNBC  
Joohyuk Sohn (Yonsei University College of Medicine)

---

**Symposium 14**  
**Microenvironment and tumorigenesis 2**

*Joint Symposium (KCA & Shanghai Cancer Institute)*

| Chairs | Wei-Qiang Gao (Shanghai Cancer Institute, China)  
| Sung Gil Chi (Korea University) |  

**SP14-1** Rac GTPase Activating Protein 1 promotes hepatocellular carcinoma growth by suppressing hippo pathway and ensuring cytokinesis in coordination with Yes-associated protein regulated nucleoporin TPR  
Zhi-Gang Zhang (Shanghai Cancer Institute, China)

**SP14-2** Tumor microenvironment in ovarian cancer: a bioinformatics perspective  
Guanglei Zhuang (Shanghai Cancer Institute, China)

**SP14-3** Systems pharmacology approaches for target & drug discovery towards cancer precision medicine  
Wankyu Kim (Ewha Womans University)

**SP14-4** Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer  
Hyuk-Jin Cha (Seoul National University College of Pharmacy)
**Master Class 3 ENG**

Towards personalised healthcare: Overcoming the challenges of NGS-based cancer profiling

Chair  Jin Haeng Chung (Seoul National University Bundang Hospital)

MC3-1  Bioinformatics perspective: technical challenges in the NGS data analysis
       Sangwoo Kim (Yonsei University College of Medicine)

MC3-2  Pathologist perspective: better use of limited precious samples
       Yoon-La Choi (Sungkyunkwan University School of Medicine)

MC3-3  Oncologist experiences: clinical application of comprehensive genomic profiling
       Kyu-pyo Kim (University of Ulsan College of Medicine)

**International Session 2 ENG**

Basic research 2

Chairs  Gi Jeong Cheon (Seoul National University Hospital)
        Chae-Yong Kim (Seoul National University Bundang Hospital)

IS02-1  Is inverse cancer comorbidity of patients with neurologic diseases real or illusion? A Korean nationwide population-based study
        Yoon Young Choi (Yonsei University Health System)

IS02-2  Prediction of pseudoprogression versus progression using machine learning algorithm in glioblastoma
        Bum-Sup Jang (Seoul National University Hospital)

IS02-3  Development and validation of machine learning mobile application “ImmunoGenius” for diagnosing tumors of unknown origin with immunohistochemistry profile using 1000 real case dataset
        Yosep Chong (The Catholic University of Korea College of Medicine)

IS02-4  Determining the optimal cervical carcinoma screening method in HIV positive and HIV negative Cambodian Women
        Sovannara Thay (Sihanouk Hospital Center of HOPE, Cambodia)

**International Session 3 ENG**

Basic research 1

Chairs  Sang-Jun Ha (Yonsei University)
        Sook Ryun Park (University of Ulsan College of Medicine)

IS01-1  Big data based clinical predictive modeling in immuno-oncology
        Su Bin Lim (National University of Singapore, Singapore)

IS01-2  Oncolytic vaccinia virus and anti-PD1-based combination therapy restores antitumor immunity in tumor microenvironment
        Badrinath Narayanasamy (Pusan National University)

IS01-3  Induction of chemokine receptor and suppression of inhibitory receptors of CD8 T cell effectively controlled HPV-associated tumor
        Sung-Jong Lee (St. Vincent’s Hospital, The Catholic University of Korea)

IS01-4  Unleashing the therapeutic potential of CAR-T therapy using CRISPR/Cas9-mediated DGK knockout
        Inyoung Jung (ToolGen)

**International Session 2 ENG**

Lung and H&N cancer

Chairs  Hoon Kyo Kim (National OncoVenture)
        Keon Uk Park (Keimyung University School of Medicine)

IS03-1  Targeted sequencing analysis of pulmonary adenocarcinoma with multiple synchronous ground-glass/lepidic nodules
        Eunhyang Park (Seoul National University College of Medicine, Bundang Hospital)

IS03-2  Association of TP53 and CDH1 gene polymorphisms with lung, breast and colorectal cancer in the Bangladeshi population
        Mohammad Safiqul Islam (Noakhali Science and Technology University, Bangladesh)

IS03-3  Is stereotactic body radiotherapy for ultracentral lung tumor a feasible option? A systemic review and meta-analysis
        Chai Hong Rim (Korea University College of Medicine)

IS03-4  NOP14 promotes nasopharyngeal carcinoma progression by up-regulating mTORC2-AKT signaling
        Bo-Hua Kuang (Wuhuan Union Hospital, China)
**International Session 4**

**GI cancer 1 (HBP, Colorectal)**

**Chairs**
In Ja Park (University of Ulsan College of Medicine)
Hye Jin Choi (Yonsei University College of Medicine)

**IS04-1**
Clinical benefit of maintenance therapy for patients with advanced biliary tract cancer without progression on first line gemcitabine plus cisplatin
Jae Won Hyung (Asan Medical Center)

**IS04-2**
Effect of sarcopenic obesity on postoperative pancreatic fistula after pancreaticoduodenectomy in patients with pancreas head cancer
Youngju Ryu (Samsung Medical Center; Sungkyunkwan University School of Medicine)

**IS04-3**
Gold nanoparticles adhered and paclitaxel-loaded PLGA microspheres for synergistic chemo-photothermal treatment of pancreatic cancer
Asmita Banstola (Keimyung University College of Pharmacy)

**IS04-4**
Two regimens of intraperitoneal chemotherapy after cytoreductive surgery improved survival of patients with colorectal peritoneal metastases
Soo Yeun Park (Kyungpook National University School of Medicine)

**International Session 5**

**Radiation oncology**

**Chairs**
Dang Huy Quoc Thinh (Hochiminh City Oncology Hospital, Vietnam)
Il Han Kim (Seoul National University College of Medicine)

**IS05-1**
Validation of a novel molecular RPA categories in glioblastoma treated with radiotherapy and concurrent temozolomide: an Asian multi-institutional study
Chan Woo Wee (Seoul National University Bundang Hospital)

**IS05-2**
The feasibility of spinal stereotactic ablative radiosurgery for spinal metastasis with epidural cord compression
Yi-Jun Kim (Seoul National University Hospital)

**IS05-3**
 Concurrent chemoradiotherapy for cervical cancer in a single institution: high-dose rate brachytherapy vs helical tomotherapy
Seongmin Kim (Korea University College of Medicine)

**Oral Presentation 1**

**Basic research (Colorectal cancer)**

**Chairs**
Jong Gwang Kim (Kyungpook National University School of Medicine)
Hye Seung Lee (Seoul National University College of Medicine)

**OP1-1**
A targeted approach toward APC-mutated colorectal cancer
Sang Bum Kim (Yonsei University College of Medicine)

**OP1-2**
Mutant KRAS-induced macrophage migration inhibitory factor (MIF) secretion promotes resistance to EGFR-blockade in colorectal cancer
Jee Eun Jang (Seoul National University)

**OP1-3**
Identification of biomarker to predict response for preoperative chemoradiotherapy using comprehensive miRNA analysis in patient with rectal cancer
Dongwon Baek (Kyungpook National University School of Medicine)

**OP1-4**
Mutational profiles of anal squamous cell carcinomas using whole-exome sequencing
Sun Shin (The Catholic University of Korea)

**OP1-5**
STING-dependent signaling underlies IL-10 controlled inflammatory colitis
Jeonghyun Ahn (University of Miami, USA)

**OP1-6**
SNAI1 and FBXL5 as potential novel biomarker for colorectal cancer
Hee Dong Koh (Yonsei University College of Medicine)
Oral Presentation 2  
Supportive care, pediatric cancer and radiation oncology

**Chairs**
Byung-Kiu Park (National Cancer Center)
Jung Hun Kang (Gyeongsang National University School of Medicine)

**OP2-1**
A phase II study to assess the immunogenicity and safety of a 13-valent pneumococcal conjugated vaccination during adjuvant chemotherapy
Woo Kyun Bae (Chonnam National University Hwasun Hospital)

**OP2-2**
Multicenter feasibility study of physician orders for life-sustaining treatment (POLST) for terminal cancer patients
Ho Jung An (The Catholic University of Korea College of Medicine)

**OP2-3**
Analysis of the socioeconomic factors for renouncing further active therapy for the patients with brain metastasis of non-small cell lung cancer
Young Zoon Kim (Samsung Changwon Hospital, Sungkyunkwan University School of Medicine)

**OP2-4**
Neurocognitive and psychological function in pediatric patients with brain tumor: pretreatment and follow-up evaluation
Boram Ha (Proton Therapy Center, National Cancer Center)

**OP2-5**
Treatment outcomes of radiotherapy for primary spinal cord glioma
Seo Hee Choi (Yonsei Cancer Center, Yonsei University College of Medicine)

---

Outstanding Abstract Session

**Chairs**
Sung Hoon Noh (Yonsei University College of Medicine)
Chang-Yuil Kang (Seoul National University College of Pharmacy)

**OAS-1**
Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: Five year survival outcome from a randomized phase II multicenter clinical
Young-Woo Kim (National Cancer Center)

**OAS-2**
YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC
Wonyoung Choi (KAIST)

**OAS-3**
Extrinsic phagocyte-dependent STING-signaling dictates the immunogenicity of dying cells
Jeonghyun Ahn (University of Miami, USA)

---

International Session 6

**Basic research 3**

**Chairs**
Tae Hyun Kim (National Cancer Center)
Kyong-Hwa Park (Korea University College of Medicine)

**IS06-1**
Time sequential changes of epithelial-mesenchymal transition signaling induced by ionizing radiation using next-generation sequencing in glioblastoma
Yi-Jun Kim (Seoul National University Hospital)

**IS06-2**
Cutting-edge research in basic and translational heavy-ion radiobiology: Focused on radioresistant cancer stem cells
Sei Sai (National Institutes for Quantum and Radiological Science and Technology, Japan)

**IS06-3**
Exploring the interaction of tumor cells and tumor-associated macrophages in colorectal cancer progression
Yeo Song Lee (Samsung Medical Center)
**Oral Presentation 3  **
**H&N and other cancers**

09:00-10:00, Sapphire Ballroom A (3F)

**Chairs**
Ho Yeong Lim (Sungkyunkwan University School of Medicine)
Sung Hwan Kim (The Catholic University of Korea College of Medicine)

**OP3-1**
The prognostic value of albumin-to-alkaline phosphatase ratio before radical radiotherapy in patients with non-metastatic nasopharyngeal carcinoma
Jae Sik Kim (Seoul National University College of Medicine)

**OP3-2**
Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement
Jiyeon Hyeon (Incheon St. Mary’s Hospital, the Catholic University of Korea College of Medicine)

**OP3-3**
Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study
Yoon-Koo Kang (University of Ulsan College of Medicine)

**OP3-4**
Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of vater
Min Hwan Kim (Yonsei University College of Medicine)

**OP3-5**
A 4-gene signature for prediction of gastric cancer prognosis based on SVM
Yoon Ho Ko (Uijeongbu St. Mary’s Hospital, the Catholic University of Korea College of Medicine)

---

**Oral Presentation 4  **
**Colorectal cancer**

09:00-10:00, Sapphire Ballroom B (3F)

**Chairs**
Tae Won Kim (University of Ulsan College of Medicine)
Jin Kim (Korea University College of Medicine)

**OP4-1**
Pilot study of neoadjuvant chemotherapy with three cycles of capecitabine and oxaliplatin (CAPOX) for treatment of locally advanced colon cancer
Soo Yeun Park (Kyungpook National University School of Medicine)

**OP4-2**
Impact of lymph node metastasis on oncologic outcomes of ypT0-2 rectal cancer treated with preoperative chemoradiotherapy: Not ignorable
Eunhae Cho (University of Ulsan College of Medicine and Asan Medical Center)

**OP4-3**
Neoadjuvant rectal score as a potential surrogate marker for the prognosis of rectal cancer: a study from two institutions
Chang Woo Kim (Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine)

**OP4-4**
Identification of novel biomarker for predicting pathologic complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
In Hee Lee (Kyungpook National University Chilgok Hospital)

**OP4-5**
Cancer chemotherapy activates type I IFN signaling through STAT1/2-mediated high order chromatin structure
Jiwon Nam (Seoul National University College of Medicine)
### International Session 7  
**Lung cancer**

**Chair**  
Jin Hyuk Choi (Ajou University School of Medicine)

**IS07-1 Cell-free DNA quantification reflects survival in non-small cell lung cancer patients with low metabolic tumor burden**  
Yoon Ji Choi (Korea University College of Medicine)

**IS07-2 Integrin β3 inhibition enhances the antitumor activity of ALK inhibitor in ALK-rearranged non-small cell lung cancer**  
Mi-Sook Lee (Sungkyunkwan University School of Medicine)

**IS07-3 Impact of FDG PET/CT in selection of patients for adjuvant chemotherapy in stage IA non-small cell lung cancer**  
Hye Lim Park (Seoul St. Mary’s Hospital, the Catholic University of Korea College of Medicine)

---

### Plenary Lecture 3

**Plenary Lecture 3**  
10:20-10:50, Crystal Ballroom (2F)

**Chair**  
Hee-Sug Ryu (Ajou University School of Medicine)

**PL3 Translational research in surgical oncology**  
Dong-Young Noh (Seoul National University College of Medicine)

---

### Plenary Lecture 4

**Plenary Lecture 4**  
10:50-11:40, Crystal Ballroom (2F)

**Chair**  
Hyun Cheol Chung (Yonsei University College of Medicine)

**PL4 New ways of targeting K-Ras**  
Frank McCormick (UCSF Helen Diller Family Comprehensive Cancer Center, USA)

---

### Satellite Symposium 4

**Satellite Symposium 4**  
11:50-12:50, Crystal Ballroom (2F)

**Chair**  
Dong-Wan Kim (Seoul National University College of Medicine)

**SS4 Harnessing the power of immunotherapy and targeted therapy in lung cancer**  
Harald A. Weber (Roche, Singapore)

---

### Satellite Symposium 5

**Satellite Symposium 5**  
11:50-12:50, Sapphire Ballroom B (3F)

**Chair**  
Min-Hee Ryu (University of Ulsan College of Medicine)

**SS5 Current status and real world experience of anti-angiogenesis in advanced gastric cancer**  
Taroh Satoh (Osaka University Graduate School of Medicine, Japan)

---

### Satellite Symposium 6

**Satellite Symposium 6**  
11:50-12:50, Sapphire Ballroom C (3F)

**Chair**  
Joo Hang Kim (CHA University School of Medicine)

**SS6 Reassuring the absolute survival benefit of ALK sequential therapy and the value of First-in-class ROS1 inhibitor**  
Yasushi Goto (National Cancer Center Hospital, Japan)

---

### Special Lecture

**Special Lecture**  
12:50-13:20, Sapphire Ballroom B (3F)

**Chair**  
Tae You Kim (Seoul National University College of Medicine)

**SL MicroDNA: Discovery of extrachromosomal circles of DNA and their roles in cancer**  
Anindya Dutta (University of Virginia School of Medicine, USA)
Symposium 15  National OncoVenture Symposium

Promising anti-cancer drug pipeline in pre-clinical and clinical stages in Korea

Chairs
Hoon Kyo Kim (National OncoVenture)
Doo-Hong Park (National OncoVenture)

SP15-1 Introduction of National OncoVenture: a Korean national anti-cancer drug development program
Young-Whan Park (National OncoVenture)

SP15-2 First-in-human phase 1 trial of HGF antibody (NOVI105, YYB101) in refractory solid tumor
Jeeyun Lee (Sungkyunkwan University School of Medicine)

SP15-3 New vascular disrupting agent CKD-516 (NOV1204) development
Kee-Won Kim (CKD Pharm)

SP15-4 Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 (NOV1501)
Jinhyung Ahn (ABL Bio Inc.)

International Session 8

Gynecologic cancer

Chairs
Hyun Hoon Chung (Seoul National University College of Medicine)
Kyong-Hwa Park (Korea University College of Medicine)

IS08-1 Genomic profiling of the residual disease of advanced-stage ovarian cancer after neoadjuvant chemotherapy
Yong Jae Lee (Yonsei University College of Medicine)

IS08-2 Long non-coding RNAs signatures to improve prognosis prediction of endometrial cancer
Qinyang Xu (Shanghai Jiao Tong University, China)
Symposium 16  ENG
Tailored care for young women with cancer

Chairs
Si-Young Kim (Kyung Hee University School of Medicine)
Eun Sook Lee (National Cancer Center)

SP16-1 Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Yeon Hee Park (Sungkyunkwan University School of Medicine)

SP16-2 Dilemmas associated with clinical application of genetic testing for young cancer patients
Ji Soo Park (Yonsei Cancer Center)

SP16-3 Strategies for fertility preservation
Jayeon Kim (CHA University School of Medicine)

SP16-4 Screening in dense breasts: challenges and options
Woo Kyung Moon (Seoul National University College of Medicine)

International Session 9  ENG
GI cancer 2 (Esophagus, stomach, CRC)

Chair
Han-Kwang Yang (Seoul National University College of Medicine)

IS09-1 Early prediction of response to radiotherapy using inter-fractional 18F-FDG PET/CT in esophageal cancer
Nalee Kim (Yonsei University College of Medicine)

IS09-2 Low mRNA expression of STAT4 indicates worse disease free-survival in gastric adenocarcinoma
Batsaikhan Bat-Erdene (Mongolian National University of Medical Science, Mongolia)

IS09-3 A suggestion of modification of TNM staging for stage II/III gastric cancer based on prognostic single patient classifier algorithm
Won Jun Seo (Yonsei University College of Medicine)

IS09-4 Prognostic roles of perioperative body mass index and weight loss in the long-term survival of gastric cancer patients
Young Suk Park (Seoul National University Bundang Hospital)

IS09-5 Gastric cancer study: Mortality and morbidity in a tertiary cancer hospital in LMIC Nepal
Kapendra Shekhar Amatya (Nepal Cancer Hospital & Research Centre, Nepal)

IS09-6 Magnetite core-shell nanoparticle mediated delivery of LCS-1 for synthetic lethal targeted therapy of BLM-defective hct116 colorectal cancer cells
Anas Ahmad (Institute of Nano Science and Technology (INST), India)
Symposium 17  
**Recent updates and future perspectives on the hepato-biliary cancer**  
13:40-15:20, Sapphire Ballroom A (3F)

**Chairs**  
Joongwon Park (National Cancer Center)  
Hyeon Kook Lee (Ewha Womans University College of Medicine)

**SP17-1**  
Recent advances in HCC systemic therapy - Where do we go from here?  
Ahmed Kaseb (MD Anderson Cancer Center, USA)

**SP17-2**  
Now, we’re getting immune-therapy in hepatocellular carcinoma  
Masafumi Ikeda (National Cancer Center Hospital East, Japan)

**SP17-3**  
Recent treatment updates on biliary tract cancer  
Do-Youn Oh (Seoul National University College of Medicine)

Symposium 18  
**Current debate in the oncologic management of rectal cancer**  
13:40-15:20, Sapphire Ballroom B (3F)

**Chairs**  
Woo Yong Lee (Sungkyunkwan University School of Medicine)  
Joonseok Lim (Yonsei University College of Medicine)

**SP18-1**  
Total neoadjuvant therapy (TNT) for rectal cancer  
Hyung Jin Kim (The Catholic University of Korea College of Medicine)

**SP18-2**  
Can radiation be omitted?  
Se-Jin Baek (Korea University College of Medicine)

**SP18-3**  
Update MR imaging in rectal cancer  
Seung Hyun Cho (Kyungpook National University School of Medicine)

**SP18-4**  
Prevention and prediction of local recurrence after curative rectal cancer surgery  
Soo Yeon Park (Kyungpook National University School of Medicine)

Symposium 19  
**Multi-omics approaches in cancer research**  
13:40-15:20, Sapphire Ballroom C (3F)

**Chairs**  
Yeun-Jun Chung (The Catholic University of Korea College of Medicine)  
Hyoung-Pyo Kim (Yonsei University College of Medicine)

**SP19-1**  
Chemical genomics approach for discovery of EMT-subtype selective intervention opportunities  
Hyun Seok Kim (Yonsei University College of Medicine)

**SP19-2**  
nc886, a non-coding RNA induced by TGF-β, modulates global gene expression by inhibiting the miRNA pathway  
Yong Sun Lee (National Cancer Center)

**SP19-3**  
Proteomic multi-marker panel improves diagnostic performance of early hepatocellular carcinoma  
Youngsoo Kim (Seoul National University College of Medicine)

**SP19-4**  
A transfer-RNA-derived small RNA affects translation in rapidly dividing cells and a target for hepatocellular carcinoma  
Hak Kyun Kim (Stanford University, USA)

Master Class 4  
**A forum on tumor microenvironment**  
13:40-15:20, Belle-vue Suite (36F)

**Chairs**  
Yeul Hong Kim (Korea University College of Medicine)  
Dae Young Zang (Hallym University College of Medicine)

**MC4-1**  
Targeting TME - Vasculature and Stroma  
Mariusz Lukanowski (Lilly, Denmark)

**MC4-2**  
Research Effort in TME  
Mariusz Lukanowski (Lilly, Denmark)

**MC4-3**  
Targeting TME Vasculature and GC  
Taroh Satoh (Osaka University Graduate School of Medicine, Japan)
**Symposium 20**  
From scientific lead to companion diagnostics (CDx) approval process in Korea  

15:40-17:20, Crystal Ballroom A (2F)

**Chairs**  
Gyungyub Gong (University of Ulsan College of Medicine)  
Kyoung-Mee Kim (Sungkyunkwan University School of Medicine)

**SP20-1**  
Developing ddPCR EGFR mutation test as CDx: Sharing experience for CDx approval  
Jee-Eun Kim (GENCURIX Inc.)

**SP20-2**  
Clinical NGS diagnostics: NGS assay selection, validation and approval  
Jihun Kim (University of Ulsan College of Medicine)

**SP20-3**  
Experience in NGS-based in vitro diagnostic medical device development for cancer gene testing  
Kwang Joong Kim (NGeneBio)

**SP20-4**  
Omics technology: Developing prediction assay for CDx platform in academia  
Kyoung-Mee Kim (Sungkyunkwan University School of Medicine)

---

**Symposium 21**  
Multidisciplinary care of BRCA mutation carriers  

15:40-17:20, Crystal Ballroom B (2F)

**Chairs**  
Byoung-Gie Kim (Sungkyunkwan University School of Medicine)  
Wonshik Han (Seoul National University College of Medicine)

**SP21-1**  
Genetic testing, counselling, and issues in clinical application  
Han-Byoel Lee (Seoul National University Hospital)

**SP21-2**  
Breast cancer surveillance and risk-reducing mastectomy  
Sang-Ah Han (Kyung Hee University School of Medicine)

**SP21-3**  
Ovarian cancer surveillance and risk-reducing surgery  
Myong Cheol Lim (National Cancer Center)

**SP21-4**  
Systemic therapy in ovarian cancer with BRCA mutation  
Yong Wha Moon (CHA University School of Medicine)

Discussion

---

**Symposium 22**  
Update of gastric cancer research in Korea  

15:40-17:20, Crystal Ballroom C (2F)

**Chairs**  
Jae Moon Bae (Sungkyunkwan University School of Medicine)  
Jae Yong Cho (Yonsei University College of Medicine)

**SP22-1**  
Feasibility of laparoscopic gastrectomy for advanced gastric cancer (result of COACT 1001 trial)  
Young-Woo Kim (National Cancer Center)

**SP22-2**  
Olaparib for management of advanced gastric cancer  
Do-Youn Oh (Seoul National University College of Medicine)

**SP22-3**  
Immunotherapy for advanced gastric cancer  
Yoon-Koo Kang (University of Ulsan College of Medicine)

**SP22-4**  
Role of eradication of Helicobacter pylori after endoscopic resection of gastric cancer  
Il Ju Choi (National Cancer Center)
**International Session 10**
*Basic research 4*

**Chairs**
Soo-Jong Um (Sejong University College of Life Sciences)
Kyeong Sook Choi (Ajou University School of Medicine)

**IS10-1**
Down-regulation of MicroRNA-17-5p promotes EMT by increasing vimentin in colorectal cancer
Tae Won Kim (Samsung Medical Center, Sungkyunkwan University)

**IS10-2**
Metastasis-associated tumor antigen-1 (MTA-1): A plausible biomarker for tobacco-related oral squamous cell carcinoma and suitable targets for screening high-risk population
Sadhna Aggarwal (All India Institute of Medical Sciences, India)

**IS10-3**
Discovery of bortezomib as a metastasis inhibitor to target GALNT14-TGFβ metastatic pathway by Connectivity MAP based drug repositioning
Ok-Seon Kwon (Seoul National University)

**IS10-4**
In-house LAMP and nPCR for detection of HPV 16 in oral cancer patients: comparision of isothermal and thermal technique
Nurul Izzati Hamzan (Universiti Sains Malaysia, Malaysia)

**IS10-5**
MAPKAPK5 inhibition suppresses YAP-driven tumorigenesis
Min Hwan Kim (Yonsei University College of Medicine)

---

**International Session 11**
*Head and neck cancer*

**Chairs**
Zeba Aziz (Hameed Latif Hospital, Pakistan)
Chul-Ho Kim (Ajou University School of Medicine)

**IS11-1**
Betel quid habits and risk of precancerous oral lesions among Paniya tribes of Wayanad, India - a cross-sectional study
Shanavis Paliyil (DM Wayanad Institute of Medical Sciences, India)

**IS11-2**
Changes in the survival rates for and curability of HPV-related and non-HPV-related head and neck squamous cell carcinomas over 40 years: a population-based analysis using the SEER program
Yi-Jun Kim (Seoul National University Hospital)

**IS11-3**
Immunoeexpression of deltaNp63 in oral squamous cell carcinoma and its relationship to histological grades of malignancy
Shakil Moidin (Al Rass Dental College, Saudi Arabia)

**IS11-4**
Detection of oral human papillomavirus in smoker and non-smoker subjects
Fatin Hazwani Fauzi (Universiti Sains Malaysia, Malaysia)

---

**Symposium 23**
*Tumor immunity and immunotherapy*

**Chairs**
Ping Zhao (China Cancer Foundation, China)
Sang-Gyu Lee (Yonsei University)

**SP23-1**
Status of immunotherapy for cancer patients in China
Lihui Zou (Beijing Medical Association, China)

**SP23-2**
Regular T cells and their potential in clinical application
Xundong Wei (Biotherapy Center, Beijing Hospital, China)

**SP23-3**
Comprehensive assessment of tumor microenvironment for precision immune-oncology
Byoung Chul Cho (Yonsei University College of Medicine)

**SP23-4**
Overcoming immune cell exhaustion by a new APC based vaccine
Chang-Yuil Kang (Seoul National University College of Pharmacy)
International Session 12  ENG  15:40-16:10, Sapphire Ballroom C (3F)
Genitourinary cancer

Chairs  Hanjong Ahn (University of Ulsan College of Medicine)
        Hyo Jin Lee (Chungnam National University School of Medicine)

IS12-1  Mini laparotomy retropubic radical cystoprostatectomy
        in elderly: Its feasibility
        Robin Joshi (Kathmandu Medical College and Nepal Cancer Hospital, Nepal)

IS12-2  Combined blockade of PI3K/AKT and AR pathway with Phloretin
        as combination therapy in pre-clinical and patient derived xenografts of
        enzalutamide-resistant prostate cancer
        Sarita Saraswati (King Saud University, Saudi Arabia)

Poster Presentations

Oral Presentation 6  KOR  16:10-16:40, Sapphire Ballroom C (3F)
Genitourinary cancer

Chairs  Hanjong Ahn (University of Ulsan College of Medicine)
        Hyo Jin Lee (Chungnam National University School of Medicine)

OP6-1  Antitumor effects of recombinant mycobacterium bovis bacillus
        Calmette-Guérin (rBCG) on bladder cancer cells
        Min Ji Cho (Chung-Ang University College of Medicine)

OP6-2  Psychiatric comorbidities among prostate cancer survivors
        in South Korea: A nationwide population-based, longitudinal study
        Jaesung Heo (Ajou University School of Medicine)
**Poster Presentation 1**

**P001**  A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with glioblastoma multiforme in the cancer genome atlas (TCGA) dataset: Integrative analyses of transcriptome and methylome  
Bum-Sup Jang (Seoul National University Hospital)

**P002**  Computational oncology prediction model algorithm  
Hyunjo Kim (Ajou Medical Center)

**P003**  Novel oncolytic virus armed with cancer suicide gene and normal vasculogenic gene for improved cancer specificity  
Su-Nam Jeong (Pusan National University)

**P004**  From cerebral vasculature to prostate cancer: Unexpected function of cerebral cavernous malformation 1 gene in progression of prostate cancer  
Yejin Kim (Gachon University)

**P005**  Induction of apoptosis by lupeol in human lung carcinoma cells through suppression of STAT3 activation  
Shin-Hyung Park (College of Korean Medicine, Dongeui University)

**P006**  Selective delivery of camptothecin to cancer cells using biotin functionalized human serum albumin conjugated nanoparticles  
Manu Sharma (M. M. College of Pharmacy, M. M. Deemed University, India)

**P007**  Development of elastin-like polypeptide for targeted nucleic acid transfer to tumor cells  
Aena Yi (Kyungpook National University)

**P008**  Histone variant H3.3 G34W substitution in giant cell tumor of the bone leads to CDKN2A DNA hypermethylation and transcriptional silencing  
Ha Nguyen (National Cancer Center)

**P009**  Decursin inhibits tumor growth, migration, and invasion in gastric cancer through the regulation of CXCR7 expression  
Solbi Kim (Chungnam National University School of Medicine)

**Poster Presentation 1**

**P010**  GRP: A novel marine derived recombinantly expressed antimicrobial peptide (AMP) retain anticancer activity against human cervical carcinoma (HELA) and colon carcinoma (HT-29) cell lines  
Anju Antony (Cochin University of Science and Technology, India)

**P011**  A thrombolytic nanocage designed to target and dissolve fibrin clots aids drug penetration in tumor  
In Seon Jeon (Kyungpook National University College of Medicine)

**P012**  Farnesyl diphosphate synthase is important for maintenance of glioblastoma stemness  
Hee Yeon Kim (National Cancer Center)

**P013**  Prognostic impact of KRAS G12D in circulating tumor DNA in pancreatic ductal adenocarcinoma  
Min Kyeong Kim (National Cancer Center)

**P014**  CARMIL3 promotes tumor progression in triple negative breast cancer: A possible novel biomarker  
Soo Jung Lee (Kyungpook National University Hospital)

**P015**  Genetic variant spectrum in 265 Chinese patients with hemophagocytic lymphohistiocytosis: molecular analyses of PRFI, UNC13D, STX11, STXB2, SH2D1A, and XIAP  
Yu Zhang (Hebei Yanda Lu Daopei Hospital, China)

**P016**  Prevalence and clinical interpretation of likely pathogenic and pathogenic variants of 23 cancer susceptibility genes detected by multigene panel testing in selected hereditary breast/ovarian cancer  
Jungah Choi (National Cancer Center)

**P017**  Clinical significance of survival specific mutational markers of clear cell renal cell carcinoma in other types of renal cell carcinoma  
Han-Jun Cho (Catholic University College of Medicine)

**P018**  Survival specific mutational makers of clear cell renal cell carcinoma extracted by machine learning  
Han-Jun Cho (Catholic University College of Medicine)
**Poster Presentation 1**

09:00-17:00, Emerald Room (2F)

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Presenter/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>P019</td>
<td>Mutational classifiers of stage progression based on feature selection models trained by machine learning algorithms in clear cell renal cell carcinoma</td>
<td>Yeong-Jin Choi (The Catholic University College of Medicine)</td>
</tr>
<tr>
<td>P020</td>
<td>NORE1A/RASSF5 directly antagonizes TNF receptor activity through the assembly of an ITCH-mediated destruction complex</td>
<td>Kyung-phil Ko (Korea University)</td>
</tr>
<tr>
<td>P021</td>
<td>XAF1 drives apoptotic switch of glioma cell response to temozolomide through activation of AMP-activated protein kinase</td>
<td>Torlo Kollie (Korea University)</td>
</tr>
<tr>
<td>P022</td>
<td>Downregulation of glycine decarboxylase is associated with chemoresistance</td>
<td>So-Jin Shin (Keimyung University School of Medicine)</td>
</tr>
<tr>
<td>P023</td>
<td>Identification of hereditary malignancy in gynecologic cancer based on gene sequencing utilizing possible screening methods by a surgeon and counselor</td>
<td>Min Kyu Kim (Samsung Changwon Hospital)</td>
</tr>
<tr>
<td>P024</td>
<td>Proteome-wide identification of symmetric arginine dimethylation in colorectal cancer tissues from patients</td>
<td>Yongchul Lim (Sungkyunkwan University School of Medicine)</td>
</tr>
<tr>
<td>P025</td>
<td>Effects of proton beam irradiation on energy metabolism in a human colorectal adenocarcinoma cell line</td>
<td>Yun-Hee Shon (Kyungpook National University Hospital)</td>
</tr>
<tr>
<td>P026</td>
<td>Enhancement of radiation-induced cell death of non-small cell lung carcinoma by modulated electro-hyperthermia</td>
<td>Suzy Kim (Seoul National University Boramae Medical Center)</td>
</tr>
<tr>
<td>P027</td>
<td>The effect of radiation on circulating tumor DNA in various non-small cell lung cancer cell lines</td>
<td>Won-Gyun Ahn (Samsung Medical Center)</td>
</tr>
<tr>
<td>P028</td>
<td>Identification of putative biomarkers for proton beam therapy in triple negative breast cancer treatment</td>
<td>Sohee Park (Samsung Medical Center)</td>
</tr>
<tr>
<td>P029</td>
<td>Targeting pH regulators as a promising strategy to enhance efficacy of radiation therapy</td>
<td>Arang Son (Samsung Medical Center)</td>
</tr>
<tr>
<td>P030</td>
<td>Establishment and drug screening in trastuzumab resistant HR-/HER2+ breast cancer patient-derived tumor xenograft (PDX) model</td>
<td>Jin-Sun Ryu (National Cancer Center)</td>
</tr>
<tr>
<td>P031</td>
<td>Impact of neoadjuvant chemotherapy on tumor infiltrating dendritic cell in esophageal squamous cell carcinoma</td>
<td>Junya Nishimura (Osaka City University Graduate School of Medicine, Japan)</td>
</tr>
<tr>
<td>P032</td>
<td>MITF is involved in the migration and invasion of renal carcinoma cells</td>
<td>Nayoung Kim (Chungnam National University)</td>
</tr>
<tr>
<td>P033</td>
<td>RIP1 mediates γ-Ionizing radiation-induced invasion of non-small cell lung cancer cells via EMT</td>
<td>Jong Kuk Park (Korea Institute of Radiological and Medical Sciences)</td>
</tr>
<tr>
<td>P034</td>
<td>High-fat diet induced aberrant upregulation of axon guidance signaling promotes metastasis of PDAC</td>
<td>Xiao-Xin Zhang (Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, China)</td>
</tr>
<tr>
<td>P035</td>
<td>Co-inhibition of The Wnt/β-catenin and PI3K/Akt signaling pathways has additional anti-tumor effects in gastric cancer cells</td>
<td>Moon Young Choi (Inje University Busan Paik Hospital)</td>
</tr>
<tr>
<td>P036</td>
<td>Zeb1 is critical for RCP-induced oral cancer cell invasiveness</td>
<td>Kyung Hwa Cho (Koryang University College of Medicine)</td>
</tr>
<tr>
<td>P037</td>
<td>EZH2 mediates LPA-induced AREG expression and breast cancer cell invasion</td>
<td>Kyung Hwa Cho (Koryang University College of Medicine)</td>
</tr>
<tr>
<td>P038</td>
<td>Enhanced CCL28 expression induced by activation of Wnt signaling enables immunosuppression via recruiting Treg cells to the tumor microenvironment</td>
<td>Lu Ji (Shanghai Cancer Institute, Shanghai Jiao Tong University, China)</td>
</tr>
</tbody>
</table>
### Poster Presentation 1

**09:00-17:00, Emerald Room (2F)**

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Author and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>P039</td>
<td>Therapeutic checkpoint targets: evaluation of co-expression profiles in individual tumor and immune cells in the tumor microenvironment of FFPE tissue</td>
<td>Chelsea Lee (Molecular Diagnostics Korea Inc)</td>
</tr>
<tr>
<td>P040</td>
<td>Prognostic implications of tumor-infiltrating plasma cells and B-cells in lung adenocarcinomas</td>
<td>Hee Eun Lee (Mayo Clinic, USA)</td>
</tr>
<tr>
<td>P041</td>
<td>Cancer-associated fibroblasts enhance metastatic potential through activation of GAS6/AXL axis in gastric cancer</td>
<td>Cheong A Bae (Ajou University School of Medicine)</td>
</tr>
<tr>
<td>P042</td>
<td>Engineering 3D multicellular cancer models for anti-cancer drug screening</td>
<td>In Yeong Bae (Ewha Womans University)</td>
</tr>
<tr>
<td>P043</td>
<td>The Combination of NVP-BEZ235 and endostatin exerts synergistic antitumor activity against triple-negative breast cancer in vitro and in vivo</td>
<td>Xiaoshan Wang (Academy of Medical Sciences &amp; Sichuan Provincial People’s Hospital, China)</td>
</tr>
<tr>
<td>P044</td>
<td>Five-year survival of Filipino women with invasive breast cancers according to clinical stages and immunohistochemistry-based molecular subtypes: a retrospective cohort study</td>
<td>Mark Ando (Perpetual Succour Hospital, Philippines)</td>
</tr>
<tr>
<td>P045</td>
<td>Understanding the experiences of breast cancer patients in Seoul, South Korea</td>
<td>Shubha Maudgal (Cancer Patients Aid Association, India)</td>
</tr>
<tr>
<td>P046</td>
<td>The relationship between serum level of copper and ceruloplasmin and pathologic and clinical characteristics in early breast cancer patients</td>
<td>Jing Fan (Xijing Hospital, Fourth Military Medical University, China)</td>
</tr>
<tr>
<td>P047</td>
<td>Preventive effect of arctigenin on metastasis in triple-negative breast cancer cells</td>
<td>Kyung-Soo Nam (Dongguk University School of Medicine)</td>
</tr>
<tr>
<td>P048</td>
<td>Generation of CDK4/6 inhibitor-resistant preclinical model in estrogen receptor-positive breast cancer</td>
<td>Kamal Pandey (CHA University)</td>
</tr>
<tr>
<td>P049</td>
<td>Estradiol mediated cell growth through HER2/COX-2 in MCF-7 mammospheres stem-like cells</td>
<td>Tsung-Hua Hsieh (Kaohsiung Medical University, Taiwan)</td>
</tr>
<tr>
<td>P050</td>
<td>A pilot study on the modulation of Hexyl-ALA-mediated PpIX generation by sex hormone in hormonal dependent breast cancer cell model</td>
<td>Kai Wai Leung (Tung Wah College, Hong Kong, China)</td>
</tr>
<tr>
<td>P051</td>
<td>Flubendazole exerts anti-tumor activity in HER2-positive breast cancer with trastuzumab resistance</td>
<td>Dael Sung (Korea University College of Medicine)</td>
</tr>
<tr>
<td>P052</td>
<td>Del-1 promotes the proliferation and migration of tamoxifen-resistant breast cancer</td>
<td>Soo Jung Lee (Kyungpook National University Hospital)</td>
</tr>
<tr>
<td>P053</td>
<td>Liver failure result from liver metastasis in an advanced breast cancer patient with BRCA2 mutation, who responded to Olaparib plus endocrine therapy</td>
<td>Jing Fan (Xijing Hospital, Fourth Military Medical University, China)</td>
</tr>
<tr>
<td>P054</td>
<td>Characteristics and treatment prognosis of male breast cancer</td>
<td>Hongliang Wei (Xijing Hospital, Fourth Military Medical University, China)</td>
</tr>
<tr>
<td>P055</td>
<td>The relationship between the expression of EZH2 and p53 protein and pathological features of TNBC patients</td>
<td>Ge Zhao (Xijing Hospital, Fourth Military Medical University, China)</td>
</tr>
<tr>
<td>P056</td>
<td>Profile and outcome of triple negative breast cancer at a tertiary care university hospital in Nepal</td>
<td>Suman Khanal (Tribhuvan University Teaching Hospital, Nepal)</td>
</tr>
<tr>
<td>P057</td>
<td>FBXO15-mediated degradation of STAT3 suppresses metastatic ability of triple-negative breast cancer</td>
<td>Nayeon Shim (Research Institute for Nature Sciences, Hanyang University)</td>
</tr>
</tbody>
</table>
**Poster Presentation 1**

09:00-17:00, Emerald Room (2F)

---

**P058** Disulfiram elicits anti-proliferative effects in ER-positive breast cancer via p53 activation and targeting cancer stem-like properties  
Seojin Jang (Korea University College of Medicine)

**P059** The clinical significance of EGFR and/or HER2 positive breast cancer and interaction with tumor associated macrophages  
Daeun You (Sungkyunkwan University)

**P060** Assessment of ki-67 and its association with clinicopathological parameters and molecular subtypes in Nepalese breast cancer  
Suniti Shrestha (Nepal Cancer Hospital & Research Center, Nepal)

**P061** Utility of early metabolic response by 18F FDG-PET/CT in a luminal-type breast cancer patients receiving neoadjuvant chemotherapy  
In Hee Lee (Kyungpook National University Chilgok Hospital)

**P062** Preclinical evaluation of selective inhibitors of nuclear export (KPT330) in breast cancer  
In Hae Park (National Cancer Center)

**P063** Risk of radiation pneumonitis following individualized radiotherapy with the cutting-edge technique for breast cancer  
Jee Suk Chang (Yonsei Cancer Center, Yonsei University College of Medicine)

**P064** Tumor infiltrating lymphocytes and breast cancer: course of disease and prognosis  
Alisher Kakhkharov (Tashkent Medical Academy, Uzbekistan)

**P065** Hepatic metastasis as a prognostic marker in metastatic breast cancer (MBC)  
Eun Kyo Joung (Incheon St. Mary’s Hospital)

**P066** Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: Prediction of distant failure risks in contemporary clinical practice  
Yu Jin Lim (Kyung Hee University Medical Center)

**P067** Roles of two stem cell markers, CD10 and CD44 in the progression of high-grade ductal carcinoma in situ into microinvasive carcinoma of the breast  
Na Hye Myung (Dankook University College of Medicine)

---

**Poster Presentation 1**

09:00-17:00, Emerald Room (2F)

---

**P068** Clinicopathological and molecular analysis of mucinous breast cancer  
Seok Yun Kang (Ajou University Hospital)

**P069** Phenotypic screening and data mining platform for cancer precision medicine  
Sukjoon Yoon (Sookmyung Women’s University)

**P070** Bioactive compounds from marine bacteria and fungi: anti-breast cancer activity and NRPS-PKS gene expression  
Farha Kabeer (Cochin University of Science and Technology, India)

**P071** Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer  
Yong-il Kim (Asan Medical Center)

**P072** Prognostic value of 11C-methionine positron emission tomography using metabolic and volumetric parameters in glioma  
Yong-il Kim (Asan Medical Center)

**P073** Impact of pulmonary tuberculosis on the EGFR mutational status and clinical outcome in patients with lung adenocarcinoma  
Seung Hyeun Lee (Kyung Hee University School of Medicine)

**P074** Palliative care for patients with lung cancer at Pham Ngoc Thach Tuberculosis and Lung diseases Hospital, Ho Chi Minh City, Vietnam from 2012 to 2017  
Thai Phan (Pham Ngoc Thach Tuberculosis and Lung Diseases Hospital, Vietnam)

**P075** ROS1-positive non-small cell lung cancer: real-world data in Korea  
Sehhoon Park (Samsung Medical Center, Sungkyunkwan University School of Medicine)

**P076** Acquired resistance to AZD9291 as an upfront treatment in non-small cell lung cancer  
Bo Mi Ku (Sungkyunkwan University School of Medicine)
**Poster Presentation 1**

09:00-17:00, Emerald Room (2F)

**P077** Differential post TKI survival outcomes in patients with acquisition of EGFR exon 20 T790M mutations according to PD-L1 expression
Seoree Kim (The Catholic University College of Medicine)

**P078** Sox2 is not related with patient prognosis in non-small cell lung cancer
Seung-Hyun Bae (National Cancer Center)

**P079** Human leukocyte antigen class I and Programmed death-ligand 1 co-expression is an independent poor prognostic factor in adenocarcinoma of the lung
Yeon Bi Han (Seoul National University Bundang Hospital)

**P080** Mandibular mass as initial presentation of non small cell lung adenocarcinoma
Bobby De Guzman (University of the Philippines - Philippine General Hospital, Philippines)

**P081** Pulmonary thromboembolism in patients with lung cancer
Ji Hyun Yang (Yeouido St. Mary’s Hospital)

**P082** Weight loss during (chemo)-radiotherapy in locally advanced non-small cell lung cancer decreases survival
Yi-Jun Kim (Seoul National University Hospital)

**P083** De novo EGFR T790M, RAS, PIK3CA and PTEN mutations in cell free DNA in non-small cell lung cancer: What is the clinical significance of these mutations?
Won Jin Chang (Korea University College of Medicine)

**P084** Genomic profiles of a hepatoblastoma from a patient with Beckwith-Wiedemann syndrome with paternal uniparental disomy on chromosome 11p15 and germline mutation of APC and PALB2
Shinn Young Kim (St. Vincent’s Hospital, The Catholic University of Korea)

**P085** Investigation of the changes in the prostate, bladder, and rectal wall sizes during external beam radiotherapy
Osamu Tanaka (Murakami Memorial Hospital, Japan)

**P086** Strategy to improve radiotherapy with targeting centrosome clustering in breast cancer cells
Min Ho Choe (Korea Institute of Radiological and Medical Sciences)

**P087** The radiosensitizing effect and immune-modulatory function of PI4K IIIα inhibition in breast cancer model: a potential model of drug repositioning
Jimin Park (Seoul National University)

**P088** Radiation induced abscopal effect in CT26 colon cancer animal model
Kyoung-Jin Kim (Yonsei University College of Medicine)

**P089** Hospice at home is the key of breast cancer end-of-life care
Nigora Atakhanova (Tashkent Medical Academy, Uzbekistan)

**P090** Chronic recurrent stomatitis in women with breast cancer
Olga Bekjanova (Tashkent State Dentistry Institute, Uzbekistan)
<table>
<thead>
<tr>
<th>Poster Presentation 2</th>
<th>09:00-17:00, Emerald Room (2F)</th>
</tr>
</thead>
</table>
| **P091** | **Role of pictorial warning on cigarette packets in tobacco cessation**  
Clement Joy Kingsly Francis (Nestle India Limited, India) |
| **P092** | **Awareness about anti-smoking acts among general public in Gurgaon, Haryana, India**  
Clement Joy Kingsly Francis (Nestle India Limited, India) |
| **P093** | **An assessment of awareness on oral cancer among smokeless tobacco users in Rathinamangalam village, Tamil nadu, India**  
Anitha Ramesh (Meenakshi Ammal Dental College, India) |
| **P094** | **Awareness of cervical cancer and screening among rural Nepalese women**  
Anju Shrestha (Nepal Cancer Hospital & Research Center, Nepal) |
| **P095** | **Rare cancers in Korea: a population-based study**  
Young-Joo Won (National Cancer Center) |
| **P096** | **Prevalence and determinants of human papillomavirus infection and cervical intraepithelial neoplasia among female sex workers in Mumbai, India: Implications for interventions**  
Sharmila Pimple (Tata Memorial Centre, India) |
| **P097** | **Effect of estrogen on tumor progression in gastric and liver cancer xenograft models**  
Sung Ryong Oh (Dukusng Women’s University) |
| **P098** | **RacGAP1 suppresses the Hippo/YAP pathway and coordinates with YAP-targeted TPR to promote cytokinesis and growth of hepatocellular carcinoma**  
Xiao-Yan Cao (Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, China) |
| **P099** | **XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis**  
Seong-in Jeong (Korea University) |
| **P100** | **LKB1 deficiency exhibits vulnerable mitochondrial defects by rapamycin on urothelial carcinoma (URCa) cells**  
Young Mi Whang (Jung-Ang University) |

<table>
<thead>
<tr>
<th>Poster Presentation 2</th>
<th>09:00-17:00, Emerald Room (2F)</th>
</tr>
</thead>
</table>
| **P101** | **Discovery of metastasis-specific exosomal miRNAs in human colorectal cancer**  
Jee Hyun Lee (Kyungpook National University School of Medicine) |
| **P102** | **Serum exosomal microRNA-203 and microRNA-373 as non-invasive biomarkers for early diagnosis and predicting prognosis in hepatocellular carcinoma**  
Gyeonghwa Kim (Kyungpook National University School of Medicine) |
| **P103** | **Functional role of hnRNPK regulated lincRNAs in cancer progression and metastasis**  
WooJoo Lee (Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University) |
| **P104** | **ELK3 regulates pro-metastatic communication between lymphatic endothelial cells and cancer cells by exosomal miRNAs**  
Kwang-Soo Kim (CHA University) |
| **P105** | **Inhibition of OCT4-PP1 interaction to target cancer stemness**  
Bomin Song (National Cancer Center) |
| **P106** | **The p21-activated kinase 4 promotes epithelial-mesenchymal transition through Slug**  
Eun-Young Shin (Chungbuk National University College of Medicine) |
| **P107** | **High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma**  
Haijian Zhang (Affiliated Hospital of Nantong University, China) |
| **P108** | **Apatinib plus radiotherapy or not in chemotherapy-refractory recurrent or metastatic oral squamous cell carcinoma: a pilot study**  
Hui Wu (Affiliated Cancer Hospital of Zhengzhou University, China) |
| **P109** | **Tumor suppressive role of Sestrin2 during colitis and colon carcinogenesis**  
Seung-Hyun Ro (University of Nebraska - Lincoln, USA) |
| **P110** | **Epithelial-mesenchymal transition aspects in colorectal mixed adenoneuroendocrine carcinosmas (MANEC)**  
Laura Banias (University of Medicine and Pharmacy of Tirgu Mures, Romania) |
<table>
<thead>
<tr>
<th>Poster Presentation 2</th>
<th>09:00-17:00, Emerald Room (2F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P11 MicroRNA 375 regulates MTDH expression in colorectal cancer cells</td>
<td>Seol Hee Han (Wonkwang University School of Medicine)</td>
</tr>
<tr>
<td>P12 MicroRNA 196B regulates HOXA5, HOXB6 and GLTP expression levels in colorectal cancer cells</td>
<td>Soo-Cheon Chae (Wonkwang University School of Medicine)</td>
</tr>
<tr>
<td>P13 Co-existent rectal adenocarcinoma and rectal tuberculosis - a report of 2 cases</td>
<td>Crizel Denise Uy (University of the Philippines, Philippine General Hospital, Philippines)</td>
</tr>
<tr>
<td>P14 The maspin expression and tumor budding degree in colorectal cancer</td>
<td>Zsolt Kovacs (University of Medicine and Pharmacy of Targu Mures, Romania)</td>
</tr>
<tr>
<td>P15 Prevalence and risk factors of colorectal polyps and colorectal cancer at a private tertiary hospital in central luzon, philippines</td>
<td>Bobby De Guzman (Premiere Medical Center, Philippines)</td>
</tr>
<tr>
<td>P16 A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer</td>
<td>Su-Nam Jeong (Pusan National University)</td>
</tr>
<tr>
<td>P17 Doxorubicin and anti PD-L1 antibody conjugated gold nanoparticles for photo-chemotherapy of colorectal cancer</td>
<td>Fakhrossadat Emami (Keimyung University College of Pharmacy)</td>
</tr>
<tr>
<td>P18 Third line treatment with capecitabine in metastatic colorectal cancer: A single center, retrospective study</td>
<td>Joon Young Hur (Samsung Medical Center, Sungkyunkwan University School of Medicine)</td>
</tr>
<tr>
<td>P19 Colon cancer is associated with a deubiquitinating enzyme through regulating Fra-1 expression</td>
<td>Sun Il Yun (Sungkyunkwan University School of Medicine)</td>
</tr>
<tr>
<td>P20 Importance of carcinoembryonic antigen on disease control and survival in elderly rectal cancer patients with comorbid condition</td>
<td>Taeryool Koo (Hallym University Sacred Heart Hospital)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Presentation 2</th>
<th>09:00-17:00, Emerald Room (2F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P121 Prognostic value of progranulin in patients with colorectal cancer treated with curative resection</td>
<td>Dong-Hoe Koo (Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)</td>
</tr>
<tr>
<td>P122 Does gained resectability after neoadjuvant chemotherapy for colorectal cancer with liver metastasis increase chance of cure?</td>
<td>Eunhae Cho (University of Ulsan College of Medicine and Asan Medical Center)</td>
</tr>
<tr>
<td>P123 Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer</td>
<td>Dakeun Lee (Ajou University School of Medicine)</td>
</tr>
<tr>
<td>P124 Phosphorylated mTOR by signaling through EphB3 confers resistance to a selective FGFR inhibitor in SNU-16 gastric cancer cells</td>
<td>Suk young Lee (Korea University Guro Hospital)</td>
</tr>
<tr>
<td>P125 Microsatellite instability and programmed cell death-1 expression in stage II/III gastric cancer: Post-hoc analysis of the CLASSIC randomized controlled study</td>
<td>Chulkyu Roh (Yonsei University Health System)</td>
</tr>
<tr>
<td>P126 Anti-cancer drug screen identifies RNF43 and PWWP2B mutation as a novel treatment biomarker in gastric cancer patients</td>
<td>Hee Jung Sul (Hallym University Sacred Heart Hospital)</td>
</tr>
<tr>
<td>P127 A randomized, phase2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer</td>
<td>Yung-Jue Bang (Seoul National University Hospital)</td>
</tr>
<tr>
<td>P128 Clinical implication of microsatellite instability in early gastric cancer</td>
<td>Yoon Young Choi (Yonsei University Health System)</td>
</tr>
<tr>
<td>P129 Integrated mRNA-miRNA regulatory network in gastric cancer patients</td>
<td>Sung-Hwa Sohn (Hallym University Sacred Heart Hospital)</td>
</tr>
<tr>
<td>P130 Identifies ACVR2A or INO80E mutation as a novel treatment biomarker in gastric cancer patients</td>
<td>Yoo Jin Kim (Hallym University Sacred Heart Hospital)</td>
</tr>
</tbody>
</table>
## P131 Clinical significance of standard adjuvant chemotherapy in patients with Epstein-Barr virus associated gastric cancer
Dongwon Baek (Kyungpook National University School of Medicine)

## P132 Outcomes according to radiation fields of neoadjuvant chemoradiotherapy for esophageal cancer
Noorie Choi (Seoul National University College of Medicine)

## P133 Radiation therapy for bleeding from advanced gastric cancer: A systematic review
Jesang Yu (Kosin University Gospel Hospital, Kosin University College of Medicine)

## P134 Characterization and therapeutic targeting of 5-FU resistance in gastric cancer cells
Hye Jung Chang (Kyung Hee University Hospital at Gangdong)

## P135 FLOT1 is associated with HGF mediated cell invasion and proliferation by increased MMP9
Sung Ae Koh (Yeungnam University Hospital)

## P136 MMR protein immunohistochemistry predicts microsatellite instability in gastric cancer
So Young Kang (Samsung Medical Center)

## P137 Computational classification of tumor microenvironment in gastric adenocarcinomas
You Jeong Heo (SAIHST, Samsung Medical Center, Sungkyunkwan University School of Medicine)

## P138 Expression of cancer-testis antigens in gastric cancer and their associations with clinicopathological characteristics
Mi Yang (Drum Tower Hospital, Medical School of Nanjing University, China)

## P139 Hyperthermic intraperitoneal chemotherapy in ovarian cancer: a meta-analysis
Se Ik Kim (Seoul National University College of Medicine)

## P140 New approaches in the prevention and early diagnosis cervical cancer
Murod Tashmetov (Scientific and Practical Research Cancer Center Tashkent, Uzbekistan)

## P141 Role of immune system in women with ovarian cancer
Bakhodir Kurbanov (Tashkent Pediatric Medical Institute, Uzbekistan)

## P142 SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via miL1RAP-NF-κB-CD47 axis
Fei Liu (Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, China)

## P143 The cervical tissue biopsy results of the low grade abnormal findings of uterine cervical smear for 20 years at a institution
Eunseop Song (Inha University School of Medicine)

## P144 The features of cervical cancer course in HIV-infected women in association with HPV
Feruzaxon Tashmetova (Scientific and Practical Research Cancer Center Tashkent, Uzbekistan)

## P145 microRNA-381 has a critical role in ovarian cancer progression through the regulation of cell motility, growth and colony formation
ChiaYi Hsu (Kaohsiung Medical University, Taiwan)

## P146 Investigation of Hexyl-ALA mediated PpIX accumulation by sex hormone in gynecological cancer cell models: an in vitro study
Ka Wang Yip (Tung Wah College, Hong Kong, China)

## P147 Somatic variations in 42 homologous recombination genes in high-grade serous ovarian carcinomas using next-generation sequencing
Min Chul Choi (CHA Bundang Medical Center)

## P148 Psychiatric comorbidities among endometrial cancer survivors in South Korea: A nationwide population-based, longitudinal study
Jaesung Heo (Ajou University School of Medicine)

## P149 Re-irradiation using intensity-modulated radiotherapy for recurrent and second primary head and neck cancer
Seo Hee Choi (Yonsei University College of Medicine)
**Poster Presentation 2**  
09:00-17:00, Emerald Room (2F)

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>P150</td>
<td>Human papillomavirus DNA integration, but not viral methylation, is associated with malignant progression of head and neck cancers</td>
<td>Joongho Joh (University of Louisville School of Medicine, USA)</td>
</tr>
<tr>
<td>P151</td>
<td>Regulation of TLRs and NODs expression by HDAC7 inhibition in human salivary mucoepidermoid carcinoma cells</td>
<td>Mee-Young Ahn (College of Medical and Life Sciences, Silla University)</td>
</tr>
<tr>
<td>P152</td>
<td>Synchronous papillary and anaplastic thyroid cancer: a case report</td>
<td>Roizza So (University of the Philippines, Philippines)</td>
</tr>
<tr>
<td>P153</td>
<td>Modulation of MMP-2 expression by Photodynamic therapy in 2D monolayer culture and 3D spheroid culture models</td>
<td>Ricky WK Wu (Tung Wah College, Hong Kong, China)</td>
</tr>
<tr>
<td>P154</td>
<td>Head and neck cancer risk associated with the paan-chewing and oral hygiene in India: A systematic review</td>
<td>Khadeeja Shanavas (Yenepoya University, India)</td>
</tr>
<tr>
<td>P155</td>
<td>Application of de-intensified radiotherapy in elderly patients with head and neck cancer: Effects of age on patterns of care</td>
<td>Jinhyun Choi (Jeju National University Hospital, Jeju National University School of Medicine)</td>
</tr>
<tr>
<td>P156</td>
<td>Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: A meta-analysis and systematic review</td>
<td>Jeongshim Lee (Inha University Hospital)</td>
</tr>
<tr>
<td>P157</td>
<td>Biomarker analysis in circulating-cell-free DNA in patients treated with sorafenib for advanced hepatocellular carcinoma</td>
<td>Sook Ryun Park (Asan Medical Center, University of Ulsan College of Medicine)</td>
</tr>
<tr>
<td>P158</td>
<td>Analysis of donor chimerism in fingernails of recipients after allogeneic hematopoietic stem cell transplantation</td>
<td>Jiaqi Chen (HebeiYanda Lu Daopei Hospital, China)</td>
</tr>
</tbody>
</table>
### Poster Presentation 2

**09:00-17:00, Emerald Room (2F)**

<table>
<thead>
<tr>
<th>P168</th>
<th>Efficacy of oral chemotherapy in advanced pancreatic cancer as 2nd line treatment</th>
<th>Se Jun Park (Seoul St. Mary’s Hospital, the Catholic University of Korea)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P169</td>
<td>Difference of chrysin response between MIA PaCa-2 and AsPC-1 cells</td>
<td>Hyun Kyung Lim (Innovative Drug Center, Duksung Women’s University)</td>
</tr>
<tr>
<td>P170</td>
<td>Efficacy of postoperative radiotherapy using modern techniques in patients with retroperitoneal soft tissue sarcoma</td>
<td>Hyun Ju Kim (Gachon University Gil Medical Center)</td>
</tr>
<tr>
<td>P171</td>
<td>Osteosarcoma animal model using humanized NOD-SCID IL2r-null (NSG) mice</td>
<td>Yunmi Ko (Korea Cancer Center Hospital)</td>
</tr>
<tr>
<td>P172</td>
<td>Protein expression of fibroblast growth factor receptor1 (FGFR1) in soft tissue sarcomas is associated with poor prognosis regardless of tumor subtypes</td>
<td>Joon Seon Song (University of Ulsan College of Medicine, Asan Medical Center)</td>
</tr>
<tr>
<td>P173</td>
<td>Changing odds of survival over time among patients undergoing surgical resection of extremity soft tissue sarcoma</td>
<td>Ilkyu Han (Seoul National University Hospital)</td>
</tr>
<tr>
<td>P174</td>
<td>Primary leiomyosarcoma of the left atrium - a case report</td>
<td>Crizel Denise Uy (University of the Philippines - Philippine General Hospital, Philippines)</td>
</tr>
<tr>
<td>P175</td>
<td>Prognostic value of platelet-lymphocyte ratio in patients with soft-tissue sarcoma</td>
<td>In Hee Lee (Kyungpook National University Chilgok Hospital)</td>
</tr>
<tr>
<td>P176</td>
<td>Bevacizumab in small bowel adenocarcinoma: a systematic review</td>
<td>John Paulo Vergara (University of the Philippines - Philippine General Hospital, Philippines)</td>
</tr>
</tbody>
</table>
Joint Conference on Precision Medicine in Solid Tumors

November 15(Thu)-17(Sat), 2018 | Lotte Hotel Seoul, Korea

Abstract Submission Deadline: August 31 (Fri.), 2018
Early-Bird Registration Due: August 31 (Fri.), 2018

Abstract Categories
- Clinical Trials
- Diagnostics
- Epigenetics and Epigenomics
- Genetics and Genomics
- Imaging
- Immunology and Immunotherapy
- Liquid Biopsy
- Novel Targets
- Novel Technologies
- Prevention
- Systems Biology and Convergence
- Tumor Microenvironment
- Other

Co-organized by
- Korean Cancer Association
- AACR

암 환자를 위한 로슈의 혁신과 도전
Bold Innovation Beyond Boundaries for Cancer Patients

로슈는 항상 암 환자를 위해 경계를 뛰어넘는 대담한 혁신을 추구합니다.
로슈는 개개인을 위한 맞춤 진단에서부터 치료와 모니터링까지, 환자 중심의 전방위적 접근을 통해 암 환자를 위한 새로운 미래를 만들어가고 있습니다.

Roche

Secretariat of AACR-KCA Joint Conference on Precision Medicine in Solid Tumors
MCI Group / Korea
Geumcheon Bldg. 85, 460 Bongeunsa-ro, Gangnam-gu, Seoul Korea 06237
T +82 (0)2 6263 2047  E aacr-kca@mci-group.kr  W precisionmedicine2018.aacr.asia